CA3213055A1 - Crystal forms of thiophene derivatives - Google Patents

Crystal forms of thiophene derivatives

Info

Publication number
CA3213055A1
CA3213055A1 CA3213055A CA3213055A CA3213055A1 CA 3213055 A1 CA3213055 A1 CA 3213055A1 CA 3213055 A CA3213055 A CA 3213055A CA 3213055 A CA3213055 A CA 3213055A CA 3213055 A1 CA3213055 A1 CA 3213055A1
Authority
CA
Canada
Prior art keywords
ethoxy
thieno
compound
crystal form
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3213055A
Other languages
English (en)
French (fr)
Inventor
Donglei ZHANG
Liyu WANG
Xingwen Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Hemay Pharmaceutical Co Ltd
Original Assignee
Tianjin Hemay Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Hemay Pharmaceutical Co Ltd filed Critical Tianjin Hemay Pharmaceutical Co Ltd
Publication of CA3213055A1 publication Critical patent/CA3213055A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
CA3213055A 2018-05-02 2019-04-30 Crystal forms of thiophene derivatives Pending CA3213055A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810407741 2018-05-02
CN201810407741.X 2018-05-02
CA3098931A CA3098931C (en) 2018-05-02 2019-04-30 Crystal forms of thiophene derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3098931A Division CA3098931C (en) 2018-05-02 2019-04-30 Crystal forms of thiophene derivatives

Publications (1)

Publication Number Publication Date
CA3213055A1 true CA3213055A1 (en) 2019-11-07

Family

ID=68386284

Family Applications (4)

Application Number Title Priority Date Filing Date
CA3213055A Pending CA3213055A1 (en) 2018-05-02 2019-04-30 Crystal forms of thiophene derivatives
CA3098927A Active CA3098927C (en) 2018-05-02 2019-04-30 Crystal forms of thiophene derivatives
CA3098931A Active CA3098931C (en) 2018-05-02 2019-04-30 Crystal forms of thiophene derivatives
CA3099072A Abandoned CA3099072A1 (en) 2018-05-02 2019-04-30 Solid forms of thiophene derivatives

Family Applications After (3)

Application Number Title Priority Date Filing Date
CA3098927A Active CA3098927C (en) 2018-05-02 2019-04-30 Crystal forms of thiophene derivatives
CA3098931A Active CA3098931C (en) 2018-05-02 2019-04-30 Crystal forms of thiophene derivatives
CA3099072A Abandoned CA3099072A1 (en) 2018-05-02 2019-04-30 Solid forms of thiophene derivatives

Country Status (14)

Country Link
US (4) US11396518B2 (enExample)
EP (5) EP3800190A4 (enExample)
JP (5) JP7481263B2 (enExample)
KR (4) KR102686835B1 (enExample)
CN (7) CN116947878B (enExample)
AU (4) AU2019262282B2 (enExample)
BR (4) BR112020021976A2 (enExample)
CA (4) CA3213055A1 (enExample)
DK (1) DK3789389T3 (enExample)
ES (1) ES3047059T3 (enExample)
FI (1) FI3789389T3 (enExample)
PL (1) PL3789389T3 (enExample)
PT (1) PT3789389T (enExample)
WO (4) WO2019210869A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3789389T3 (pl) * 2018-05-02 2026-03-16 Tianjin Hemay Pharmaceutical Co., Ltd. Postać krystaliczna (s)-n-[5-[1-(3-etoksy-4-metoksyfenylo)-2-(metylosulfonylo)etylo]-4,6-diokso-5,6-dihydro-4h-tieno[3,4-c]pirol-1-ilo]acetamidu
WO2025103428A1 (zh) * 2023-11-14 2025-05-22 赣州和美药业股份有限公司 中重度斑块型银屑病的治疗

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
AU2003243153A1 (en) * 2002-04-23 2003-11-10 Dr. Reddy's Laboratories Limited Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof
CN101186612B (zh) 2006-11-15 2012-10-03 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用
KR101514866B1 (ko) 2009-05-14 2015-04-24 티안진 헤메이 바이오-텍 컴퍼니 리미티드 티오펜 유도체
US8946474B2 (en) * 2010-06-30 2015-02-03 Leo Pharma A/S Polymorphic form of a calcimimetic compound
CN105793251B (zh) * 2013-12-05 2018-10-12 豪夫迈·罗氏有限公司 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物
WO2016010178A1 (ko) * 2014-07-18 2016-01-21 주식회사 녹십자 5-클로로-ｎ-({(5ｓ)-2-옥소-3-[4-(5,6-디하이드로-4h-[1,2,4]트리아진-1-일)페닐]-1,3-옥사졸리딘-5-일}메틸)티오펜-2-카르복사미드 메탄설폰산염의 신규 결정형 및 이를 포함하는 약학 조성물
EP3144393A1 (en) * 2015-09-18 2017-03-22 LEK Pharmaceuticals d.d. A synthetic pathway towards apremilast
CN107417626B (zh) * 2016-05-23 2020-01-24 江苏奥赛康药业有限公司 一种2-氨基嘧啶类化合物的多晶型形式
CN107474057B (zh) * 2016-06-07 2021-03-12 天津药物研究院有限公司 (5-(2-腈基苄基)-4,5,6,7-四氢噻吩并[3,2-c]吡啶-2-基)乙酸酯盐酸盐的晶型及其制备方法和用途
US10570147B2 (en) * 2017-06-13 2020-02-25 Biotheryx, Inc. Bicyclic compounds and methods of use
EP3644860B1 (en) * 2017-06-30 2024-05-08 Trophy An extra oral dental imaging apparatus with patient positioning accessory detection
PL3789389T3 (pl) 2018-05-02 2026-03-16 Tianjin Hemay Pharmaceutical Co., Ltd. Postać krystaliczna (s)-n-[5-[1-(3-etoksy-4-metoksyfenylo)-2-(metylosulfonylo)etylo]-4,6-diokso-5,6-dihydro-4h-tieno[3,4-c]pirol-1-ilo]acetamidu

Also Published As

Publication number Publication date
EP4335515A2 (en) 2024-03-13
US11396518B2 (en) 2022-07-26
DK3789389T3 (da) 2025-11-10
AU2019263865B2 (en) 2022-01-27
JP2024026251A (ja) 2024-02-28
FI3789389T3 (fi) 2025-11-19
JP2021523935A (ja) 2021-09-09
JP2021523891A (ja) 2021-09-09
KR20210025001A (ko) 2021-03-08
EP3789388B1 (en) 2024-01-24
JP7542523B2 (ja) 2024-08-30
AU2019262282A1 (en) 2020-11-12
EP3800190A4 (en) 2022-01-26
KR20210022557A (ko) 2021-03-03
CA3098927C (en) 2023-10-03
PT3789389T (pt) 2025-12-17
CA3099072A1 (en) 2019-11-07
KR102701245B1 (ko) 2024-08-30
EP3789387B1 (en) 2024-02-28
WO2019210864A1 (zh) 2019-11-07
ES3047059T3 (en) 2025-12-03
JP2021523890A (ja) 2021-09-09
BR112020022190A2 (pt) 2021-02-02
EP3789389A4 (en) 2022-01-26
EP3800190A1 (en) 2021-04-07
CN110437251B (zh) 2023-07-21
US12180222B2 (en) 2024-12-31
CN116854705A (zh) 2023-10-10
CA3098931C (en) 2023-10-24
EP3789389A1 (en) 2021-03-10
PL3789389T3 (pl) 2026-03-16
CA3099071A1 (en) 2019-11-07
US20210380600A1 (en) 2021-12-09
US20210139498A1 (en) 2021-05-13
CN116836178A (zh) 2023-10-03
EP3789387A4 (en) 2021-06-30
BR112020021945A2 (pt) 2021-01-26
WO2019210869A1 (zh) 2019-11-07
BR112020021976A2 (pt) 2021-01-26
JP7481263B2 (ja) 2024-05-10
US12227514B2 (en) 2025-02-18
WO2019210865A1 (zh) 2019-11-07
EP4335515A3 (en) 2024-07-03
JP7477459B2 (ja) 2024-05-01
KR20210022556A (ko) 2021-03-03
AU2019262286B2 (en) 2022-08-11
JP2021522348A (ja) 2021-08-30
US20210230181A1 (en) 2021-07-29
EP3789388A4 (en) 2021-06-09
CA3098931A1 (en) 2019-11-07
WO2019210867A1 (zh) 2019-11-07
AU2019263865A1 (en) 2020-12-24
CN110437250B (zh) 2023-06-23
CN110437249B (zh) 2023-07-21
US20210238191A1 (en) 2021-08-05
CN116947878A (zh) 2023-10-27
CN116854705B (zh) 2026-06-19
CN116947878B (zh) 2026-06-19
KR20210025000A (ko) 2021-03-08
EP3789388A1 (en) 2021-03-10
US11274104B2 (en) 2022-03-15
EP3789389B1 (en) 2025-10-08
CN116813637A (zh) 2023-09-29
CN110437251A (zh) 2019-11-12
AU2019262282B2 (en) 2022-04-28
AU2019262284A1 (en) 2020-12-24
CA3098927A1 (en) 2019-11-07
KR102839924B1 (ko) 2025-07-29
EP3789387A1 (en) 2021-03-10
CN110437250A (zh) 2019-11-12
CN110437249A (zh) 2019-11-12
KR102686835B1 (ko) 2024-07-22
BR112020022186A2 (pt) 2021-02-02
AU2019262286A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
CA3098931C (en) Crystal forms of thiophene derivatives
CA3099071C (en) Crystal forms of thiophene derivatives
HK40048511A (en) Crystal form of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1-yl]acetamide
HK40047648B (en) Crystalline form of (s)‑n‑[5‑[1‑(3‑ethoxy‑4‑methoxyphenyl)‑2‑(methylsulfonyl)ethyl]‑4,6‑dioxo‑5,6‑dihydro‑4h‑thieno[3,4‑c]pyrrole‑1‑yl]acetamide
HK40048512B (en) Crystal form of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1-yl]acetamide
HK40048511B (en) Crystal form of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1-yl]acetamide
HK40047648A (en) Crystalline form of (s)‑n‑[5‑[1‑(3‑ethoxy‑4‑methoxyphenyl)‑2‑(methylsulfonyl)ethyl]‑4,6‑dioxo‑5,6‑dihydro‑4h‑thieno[3,4‑c]pyrrole‑1‑yl]acetamide
HK40048512A (en) Crystal form of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1-yl]acetamide
HK40047649A (en) Solid form of thiophene derivative

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230919

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241231

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251015

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251215

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260611